Ureteropelvic junction obstruction
ICD-10 N13.0 · ICD-11 GB56.0

Treatment of Ureteropelvic Junction Obstruction with Preserved Differential Renal Function (>40% on MAG3) and No Pain or Infection

In ureteropelvic junction obstruction, the decision between conservative management and surgical intervention depends on measurable functional and anatomical parameters. When these parameters fall within favourable thresholds and the patient is asymptomatic, a non-surgical approach is appropriate — guided by a structured, evidence-based protocol.

Clinical scenario This protocol applies to patients with ureteropelvic junction obstruction in whom all of the following are present:
  • Differential renal function of the hydronephrotic kidney >40% on MAG3 scanning
  • Anteroposterior diameter of the renal pelvis ≤20 mm on ultrasonographic scan
  • No pain
  • No urinary tract infection
Conservative management is supported when differential function of the obstructed kidney exceeds 40% and the renal pelvis diameter remains below the threshold that would otherwise indicate surgery.
Treatment approach (partial) In infants presenting with this clinical picture, management includes antibiotic prophylaxis as an initial protective measure, continued while vesicoureteric reflux is being excluded. The full protocol specifies which agents are used, the monitoring schedule, criteria for re-evaluation, and the conditions that would prompt escalation to surgical review.

Full regimen, escalation thresholds, and monitoring details are available via the structured protocol below.

References

DOI: 10.1016/j.eursup.2012.01.004

  • Conservative treatment measures, therefore, can be used if the differential renal function of the obstructed kidney is >40% and the APD is <12 mm.
  • Some indications for surgery include <40% differential function of the hydronephrotic kidney on MAG3 scanning, a >20-mm anterior-posterior diameter of the renal pelvis on ultrasonographic scan, pain, and infection.
  • Antibiotic prophylaxis—such as trimethoprim, 1–2 mg/kg at night, or cephalexin, 5 mg/kg at night—is started in infants with antenatal hydronephrosis until VUR has been excluded.
View source ↗